Landing in the world’s most dynamic tech hub, Talking Medicines is accelerating its US expansion with a strategic residency in Silicon Valley. Positioned at the crossroads of healthcare and innovation, the company is making bold moves to strengthen its AI-led impact on the pharmaceutical sector.
Talking Medicines has joined the Scottish Government and SDI’s Market Booster Programme with a prestigious placement in Silicon Valley, signalling a major leap in its US expansion strategy. This move embeds the company in the epicentre of global tech innovation, providing direct access to influential industry leaders and key players across the American healthcare landscape.
With its foundations firmly set on the East Coast through a legal entity and headquarters in New York, Talking Medicines is now setting its sights westward. The decision to enter the US market is driven by its status as the world’s leading pharmaceutical arena, offering vast potential for scaling AI-powered healthcare insights. This westward expansion enables deeper engagement with cutting-edge technologies, while also cultivating relationships with new customers and strategic partners.
Silicon Valley’s renowned focus on artificial intelligence, data science, and transformational thinking directly aligns with Talking Medicines’ mission. The residency is designed to fast-track collaboration with tech innovators and enhance the company’s AI solutions, which are centred around understanding real-world patient experiences. It’s a chance to broaden the scope of their health and wellness intelligence, solidifying their leadership in patient-centric AI.
Navigating the intricate US healthcare system is no small feat, but Talking Medicines is well-equipped. Its experience in regulatory compliance and insights into both healthcare professionals and patient behaviours allow it to tackle complexity with confidence. These challenges also provide fertile ground for innovation, encouraging the team to fine-tune their technology to the needs of the US market.
What truly distinguishes Talking Medicines is its ability to transform HCP and patient experiences into tangible insights for pharmaceutical companies and their agency partners. By applying advanced AI and data science, the platform delivers critical intelligence that supports more targeted marketing and drives better patient outcomes. It’s this precision and purpose that give Talking Medicines a clear edge.
While in Silicon Valley, the company has laid out a sharp focus: build strategic alliances with tech and healthcare leaders, recruit top-tier US talent, and connect with investors passionate about reshaping pharma marketing through AI. Being immersed in such a forward-thinking ecosystem ensures that Talking Medicines remains at the forefront of innovation.
Looking ahead, the company’s ambition is to embed itself within the fabric of the US healthcare system. Through its AI-driven tools, Talking Medicines is committed to helping pharma better understand and engage with patients and professionals alike—advancing a more effective, compassionate, and data-informed approach to care.
Talking Medicines is a pioneering healthtech company using AI and data science to capture and translate real-world patient and HCP experiences into powerful insights for pharmaceutical marketing.
Tern plc (LON:TERN) backs exciting, high growth IoT innovators in Europe. They provide support and create a genuinely collaborative environment for talented, well-motivated teams. The Talking Medicines mission is to be the World’s Gold Standard for Patient Intelligence by Medicine.
